2024 ASCO® Annual Meeting Insights Hub

Meeting coverage & Vumedi’s exclusive highlights, all in one place.

 

ASCO® 2024 Insights: "CHRYSALIS-2 Trial - Amivantamab + Lazertinib in Atypical EGFRm Advanced NSCLC"

65 views
June 14, 2024

Chapters

CHRYSALIS-2 Trial Overview & Patient Demographics

00:00

Efficacy & Safety of Amivantamab + Lazertinib

03:00

Comparative Analysis & Final Conclusions

05:47

Comments 0
Login to view comments. Click here to Login